Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04429854
Previous Study | Return to List | Next Study

Donated Antibodies Working Against nCoV (DAWN-Plasma)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04429854
Recruitment Status : Recruiting
First Posted : June 12, 2020
Last Update Posted : June 12, 2020
Sponsor:
Collaborator:
Federal Knowledge Centre (KCE)
Information provided by (Responsible Party):
Universitaire Ziekenhuizen Leuven

Brief Summary:
This a phase II, proof-of-concept study. In the present study, we investigate if the administration of blood-plasma from patients recovered from COVID-19, could be effective to treat patients who are severely ill because of a COVID-19 infection. The general idea behind the transfusion, is that plasma of recovered patients contains antibodies that could eliminate the novel coronavirus causing COVID-19, and lead to a less severe course of the disease, or a faster healing. Simply put, in this study we would like to investigate whether 'borrowed immunity' from a person who has cured from this disease, could be applied to cure other patients more rapidly.

Condition or disease Intervention/treatment Phase
COVID-19 Biological: Convalescent Plasma Drug: Standard of care Phase 2

Detailed Description:

In December 2019, a new coronavirus (the SARS-CoV-2 virus) emerged, which spread fast across the world, and has led to a pandemic. The disease caused by this virus, called COVID-19, has a mild course in a high number of infected people, but is known to have a more severe course in some. Currently, there are no successful treatments with a known effect on the course of the disease in patients suffering from COVID-19. In this study, we will examine whether plasma, a treatment that has been used in human subjects for other diseases (and is known to be safe), can be used to influence the course of COVID-19 towards a lower severity.

The aim of the study is to evaluate clinical efficacy and safety of convalescent plasma for COVID-19.

This clinical trial is an adaptive, randomized, open-label phase II proof-of-concept study to investigate the safety and effect of potentially interesting treatments, for the treatment of hospitalized adult patients suffering from COVID-19.

Because an active treatment for COVID-19 is lacking, plasma donation is now being proposed. To investigate this effect of plasma, we will compare two groups of patients. One group will get standard treatment, plus plasma from a patient recently cured from COVID-19. A second group will get standard treatment alone. In this study, 2 patients out of 3 will receive plasma, and 1 patient out of 3 will receive standard treatment alone. After the study, we will be able to establish whether plasma donation is useful or not.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 483 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 483 patients with 2:1 randomization. 322 patients receiving Convalescent Plasma - 161 patients receiving Standard of Care
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Adaptive, Proof-of-concept Clinical Trial of Donated Antibodies Working Against With COVID-19: DAWN-PLASMA
Actual Study Start Date : May 2, 2020
Estimated Primary Completion Date : November 2, 2021
Estimated Study Completion Date : November 2, 2021

Arm Intervention/treatment
Experimental: Convalescent Plasma

4 units of convalescent plasma:

  • 2 units of plasma are administered within 12h after randomization, but preferably as soon as practically possible
  • 2 units of plasma should be administered between 24h and 36h after the first infusion
Biological: Convalescent Plasma

4 units of convalescent plasma:

  • 2 units of plasma are administered within 12h after randomization, but preferably as soon as practically possible
  • 2 units of plasma should be administered between 24h and 36h after the first infusion

Other investigational products may be added as part of the adaptive study design.


Drug: Standard of care
Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.

Standard of Care
Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive. Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.
Drug: Standard of care
Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.




Primary Outcome Measures :
  1. Patients requiring mechanical ventilation or death [ Time Frame: No mechanical ventilation at day 15 after hospitalization. ]
    Primary outcome of the study is the number of patients alive without mechanical ventilation at day 15 after hospitalization.


Secondary Outcome Measures :
  1. Clinical status of subject at day 15 and day 30 (on a 10-point "WHO progression" ordinal scale) [ Time Frame: day 15 and day 30 ]

    0. Uninfected. Non viral RNA detected

    1. Ambulatory, Asymptomatic, viral RNA detected
    2. Ambulatory, Symptomatic, Independent
    3. Ambulatory, Symptomatic, Assistance needed
    4. Hospitalized, mild disease, No oxygen therapy needed
    5. Hospitalized, mild disease, Oxygen by mask of nasal prongs
    6. Hospitalized, severe disease, Oxygen by NIV or High flow
    7. Hospitalized, severe disease, Intubation and mechanical ventilation (pO2/FiO2>=150 OR SpO2/FIO2>=200)
    8. Hospitalized, severe disease, Mechanical ventilation (pO2/FiO2<150 OR SpO2/FIO2<200) OR vasopressors (norepinephrine >0.3 microg/kg/min)
    9. Hospitalized, severe disease, Mechanical ventilation pO2/FiO2<150 AND vasopressors (norepinephrine >0.3 microg/kg/min), OR Dialysis OR ECMO
    10. Death, Dead



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject (≥18 years old) or legally authorized representative provides informed consent prior to initiation of any study procedures.
  2. Subject (or legally authorized representative) understands and agrees to comply with planned study procedures.
  3. Male or non-pregnant female adult ≥18 years of age at time of enrolment.
  4. Patient should be hospitalized
  5. Has a confirmed diagnosis of SARS-CoV-2 infection, defined as either:

    1. laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen as diagnosed within 60 hours prior to randomization or
    2. The combination of upper or lower respiratory infection symptoms (fever, cough, dyspnea, desaturation) and typical findings on chest CT scan and absence of other plausible diagnoses
  6. Illness of any duration, and at least one of the following:

    1. Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), or
    2. Clinical assessment (evidence of rales/crackles on exam) AND SpO2 ≤ 94% on room air, or
    3. Requiring supplemental oxygen.
  7. ABO D typing of the patient should be done at least once and the result should be known.

Exclusion Criteria:

  1. Receiving invasive (any mode where a patient has been intubated endotracheally, or via tracheostomy) or non-invasive (for instance, but not restricted to CPAP, PSV, PCV, SiMV) mechanical ventilation before or upon randomization.
  2. Pregnancy or breast feeding.
  3. Any medical condition which would impose an unacceptable safety hazard by participation to the study.
  4. Patients with a documented grade 3 allergic reaction after the administration of fresh frozen plasma (i.e. systemic reaction with cardiovascular and/or respiratory involvement)
  5. Patients that have treatment restriction that excludes mechanical ventilation and/or endotracheal intubation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04429854


Contacts
Layout table for location contacts
Contact: Geert Meyfroidt, MD, PhD 003216332211 geert.meyfroidt@uzleuven.be

Locations
Layout table for location information
Belgium
ZNA Recruiting
Antwerpen, Belgium, 2050
Contact: Niels Van Regenmortel, MD       niels.vanregenmortel@zna.be   
Institut Bordet Not yet recruiting
Brussel, Belgium, 1000
Contact: Georgala Aspasia, MD       aspasia.georgala@bordet.be   
UMC Sint-Pieter Recruiting
Brussel, Belgium, 1000
Contact: Nicolas Dauby, MD       ndauby@ulb.ac.be   
CHU Brugmann Active, not recruiting
Brussel, Belgium, 1030
Erasmus Ziekenhuis Active, not recruiting
Brussel, Belgium, 1070
UZ Brussel Recruiting
Brussel, Belgium, 1090
Contact: Lucie Seyler, MD       Lucie.Seyler@uzbrussel.be   
Cliniques Universitaires St Luc Recruiting
Brussel, Belgium, 1200
Contact: Jean Yombi, MD       jean.yombi@uclouvain.be   
AZ Groeninge Recruiting
Kortrijk, Belgium, 8500
Contact: Matthias Leys, MD       mathias.leys@azgroeninge.be   
UZ Leuven Recruiting
Leuven, Belgium, 3000
Contact: Timothy Devos, MD,PHD       timothy.devos@uzleuven.be   
CHC Liège Mont Légia Recruiting
Liège, Belgium, 4000
Contact: Laurent Jadot, MD       Laurent.Jadot@CHC.be   
CHR Citadelle Liège Active, not recruiting
Liège, Belgium, 4000
CHU Liège Sart-Tilman Recruiting
Liège, Belgium, 4000
Contact: Michel Moutschen, MD       mmoutschen@chuliege.be   
CHR Jolimont Mons-Hainaut Recruiting
Mons, Belgium, 7100
Contact: Clotilde Visée, MD       Clotilde.VISEE@jolimont.be   
AZ Delta Recruiting
Roeselare, Belgium, 8800
Contact: Bernard Bouckaert, MD       bernard.bouckaert@azdelta.be   
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
Federal Knowledge Centre (KCE)
Investigators
Layout table for investigator information
Study Director: Geert Meyfroidt, MD, PhD UZ Leuven
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier: NCT04429854    
Other Study ID Numbers: S63992
First Posted: June 12, 2020    Key Record Dates
Last Update Posted: June 12, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No